SCHEMBL474049

SCHEMBL474049

CCCCCCCCCCCCCCCCCCOS(=O)(=O)OCCCCCCCCCCCCCCCC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 15/20 0.67
CA2 P00918 15/20 0.67
CA9 Q16790 13/20 0.67
CA12 O43570 4/20 0.67
CA7 P43166 4/20 0.67
CA14 Q9ULX7 4/20 0.67
CA3 P07451 3/20 0.67
CA4 P22748 3/20 0.67
CA6 P23280 3/20 0.67
CA5A P35218 3/20 0.67
CA5B Q9Y2D0 3/20 0.67
RECQL P46063 2/20 0.64
TSHR P16473 2/20 0.64
GLA P06280 1/20 0.64
HPGD P15428 1/20 0.64
MAPK1 P28482 1/20 0.64
EPHX2 P34913 1/20 0.64
BLM P54132 1/20 0.64
KDM4E B2RXH2 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148280 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL3354 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL41458 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL17336090 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL771183 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL2494632 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL143596 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL42396 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL147679 1.00 CA1 (0.67) CA1CA2CA9CA12CA7
SCHEMBL5199618 1.00 CA1 (0.67) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3220876-A1 PREPARATIONS CONTAINING ASCORBIC ACID, UBIDECARENONE AND AN EMULSIFIER MIXTURE Beiersdorf AG (DE) 2017-09-27 EP claimed
EP-3221013-A1 PREPARATIONS CONTAINING ASCORBIC ACID, UBIDECARENONE AND PHOSPHATE IONS, FOR IMPROVED SKIN CONTOURING OR AGAINST CELLULITE Beiersdorf AG (DE) 2017-09-27 EP claimed
WO-2016078854-A1 PREPARATIONS CONTAINING ASCORBIC ACID, UBIDECARENONE AND PHOSPHATE IONS, FOR IMPROVED SKIN CONTOURING OR AGAINST CELLULITE BEIERSDORF AG (DE) 2016-05-26 WO claimed
WO-2016078853-A1 PREPARATIONS CONTAINING ASCORBIC ACID, UBIDECARENONE AND AN EMULSIFIER MIXTURE BEIERSDORF AG (DE) 2016-05-26 WO claimed
WO-2014183973-A1 STABILIZED PREPARATIONS CONTAINING ASCORBIC ACID AND PHOSPHATE IONS BEIERSDORF AG (DE) 2014-11-20 WO claimed
WO-2014183974-A1 STABILIZED PREPARATIONS CONTAINING ASCORBIC ACID AND MIXTURES OF SODIUM STEAROYL GLUTAMATE AND/OR CETYL STEARYL SULFATE IN COMBINATION WITH GLYCERYL STEARATE BEIERSDORF AG (DE) 2014-11-20 WO claimed
WO-2013032142-A9 HIGHLY FUNCTIONAL POLYMERIZING ADDITIVE AND METHOD FOR PREPARING A VINYL CHLORIDE-BASED SEED USING SAME (주) 엘지화학 (KR) 2013-04-04 WO claimed
WO-2013032142-A2 HIGHLY FUNCTIONAL POLYMERIZING ADDITIVE AND METHOD FOR PREPARING A VINYL CHLORIDE-BASED SEED USING SAME (주) 엘지화학 (KR) 2013-03-07 WO claimed
EP-1957037-B1 PHARMACEUTICAL COMPOSITION FOR NASAL APPLICATION OF FENTANYL NASALIS PAIN RELIEF INTERNAT G (DE) 2010-04-21 EP claimed
EP-1557160-B1 Foamable cosmetic o/w-emulsion BEIERSDORF AG (DE) 2007-04-04 EP claimed
EP-0841895-B1 SLIMMING CREAM BASED ON PLANTS DOS SANTOS MOTA JOAO CARLOS (PT) 2003-04-09 EP claimed
EP-0786986-B1 Use of an unsaturated fatty alcohol NOVARTIS AG (CH) 2002-03-20 EP claimed
EP-0736299-B1 Process for preparing a liposomal, water-dispersable, solid, dry, therapeutic formulation for oral administration CERBIOS PHARMA SA (CH) 2001-11-14 EP claimed
US-5972340-A COMPRISING SEAWEEDS, CREEPING IVY, HORSETAIL, FENUGREEK, MALLOWS, WITCH HAZEL, WHEATGERM OIL, CAMPHOR, PRESERVATIVE AND EXCIPIENT DOS SANTOS GEORGINA (PT) 1999-10-26 US claimed
EP-0661047-B1 Pharmaceutical formulation containing diphenhydramine, talc, calamine and oat extract in an emulsified vehicle and uses thereof CUSI LAB (ES) 1998-01-28 EP claimed
EP-0131927-B1 PHARMACEUTICAL PREPARATION CONTAINING ISOSORBIDE DINITRATE Heinrich Mack Nachf. (DE) 1989-10-04 EP claimed
US-12415876-B2 Method for producing vinyl chloride-based polymer LG CHEM, LTD. (KR) 2025-09-16 US disclosed
US-20250161232-A1 RETINOL FORMULATION (VI) DSM IP ASSETS B.V. (NL) 2025-05-22 US disclosed
US-4084052-A HAIR DYES L'OREAL (FR) 1978-04-11 US disclosed
US-4023926-A Diaminobenzoquinones in hair dye compositions SOCIETE ANONYME DITE: L'OREAL (FR) 1977-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161232-A1 RETINOL FORMULATION (VI) RBP4, TTPA, RBP1 CA1 4759/4885CA2 4803/4885CA9 3904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.